These results imply that Thrap3 LKO restored mitochondrial dysfunction, prevented the vicious cycle leading to ROS overproduction and hepatic steatosis, and finally ameliorated the NAFLD phenotype. The gene discussed is THRAP3; the disease is metabolic dysfunction-associated steatotic liver disease.